Cyclerion Therapeutics, Inc.

Ironwood Pharmaceuticals, Inc.

Tisento Therapeutics Inc.

Thomas Wai-Ho Lee

Rajesh R Iyengar

Takashi Nakai

Paul A Renhowe

Glen Robert Rennie

Joon Jung

Ara Mermerian

Nicholas Robert Perl

G-Yoon Jamie Im

Karthik Iyer

Joel D Moore

Timothy Claude Barden

James Edward Sheppeck

Mark G Currie

Xiang Y Yu

Lei Jia

Colleen Hudson

Kimberly Kafadar Long

George Todd Milne

Kim Tang

James Jia

Peter Germano

Jason Matthew Rohde

Charles Kim

Angelika Fretzen

Brian Christopher Raudenbush

Nicholas Perl

Maria D Ribadeneira

Paul Allen Renhowe

Paul Allan Renhowe

Alan David Swinamer

Wang Mao

John Lord

Can Mao

Christian Harcken

Mark Currie

Hossein Razavi

Christopher Ronald Sarko

Brian Nicholas Cook

Pingrong Liu

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula I:

sGC stimulators

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable. The compounds are of Formula I:

SGC stimulators

The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3',5&#x2032;-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.

Treatment of CNS diseases with sGC stimulators

Compounds of Formulae I' and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed. 

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula (I). 

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable. The compounds are of Formula I: 

The present patent application discloses at least the compounds according to Formula I' shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, J, n, J, J, X, Z, Z, R, R, Y, R, o and W are as defined herein.

Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed. 

The present patent application discloses at least the compounds according to Formula I' shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, ring F, J, n, J, J, o, R, R, W, J, r, J, s, Z, Zand Zare as defined herein.

Growing community of inventors

Lexington, MA, United States of America

Thomas Wai-Ho Lee